Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer

被引:19
|
作者
Scheel, Andreas H. [1 ]
Penault-Llorca, Frederique [2 ]
Hanna, Wedad [3 ]
Baretton, Gustavo [4 ]
Middel, Peter [5 ,6 ]
Burchhardt, Judith [5 ]
Hofmann, Manfred [5 ]
Jasani, Bharat [7 ]
Rueschoff, Josef [5 ,7 ]
机构
[1] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany
[2] Ctr Jean Perrin, Dept Pathol, 58 Rue Montalembert,392, F-63011 Clermont Ferrand 1, France
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Univ Hosp Dresden, Inst Pathol, Fetscherstr 74, D-01307 Dresden, Germany
[5] Inst Pathol Nordhessen, Germaniastr 7, D-34119 Kassel, Germany
[6] Univ Hosp Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany
[7] Targos Mol Pathol GmbH, Germaniastr 7, D-34119 Kassel, Germany
来源
DIAGNOSTIC PATHOLOGY | 2018年 / 13卷
关键词
HER2/neu; Immunohistochemistry; Breast cancer; Gastric cancer; Magnification rule; Predictive biomarker; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; DIGITAL IMAGE-ANALYSIS; AMERICAN-PATHOLOGISTS; PROTEIN EXPRESSION; ADENOCARCINOMAS; REPRODUCIBILITY; RECOMMENDATIONS; PEMBROLIZUMAB; VALIDATION;
D O I
10.1186/s13000-018-0696-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas. Immunohistochemistry (IHC) of the HER2 protein is the most common screening test, thus precise and reproducible IHC-scoring is of utmost importance. Interobserver variance still is a problem; in particular in gastric carcinomas the reliable differentiation of IHC scores 2+ and 1+ is challenging. Herein we describe the physical basis of what we called the 'magnification rule': Different microscope objectives are employed to reproducibly subdivide the continuous spectrum of IHC staining intensities into distinct categories (1+, 2+, 3+). Methods: HER2-IHC was performed on 120 breast cancer biopsy specimens (n = 40 per category). Width and color-intensity of membranous DAB chromogen precipitates were measured by whole-slide scanning and digital morphometry. Image-analysis data were related to semi-quantitative manual scoring according to the magnification rule and to the optical properties of the employed microscope objectives. Results: The semi-quantitative manual HER2-IHC scores are correlated to color-intensity measured by image-analysis and to the width of DAB-precipitates. The mean widths +/- standard deviations of precipitates were: IHC-score 1+, 0.64 +/- 0.1 mu m; score 2+, 1.0 +/- 0.23 mu m; score 3+, 2.14 +/- 0.4 mu m. The width of precipitates per category matched the optical resolution of the employed microscope objective lenses: Approximately 0.4 mu m (40x), 1.0 mu m (10x) and 2.0 mu m (5x). Conclusions: Perceived intensity, width of the DAB chromogen precipitate, and absolute color-intensity determined by image-analysis are linked. These interrelations form the physical basis of the 'magnification rule': 2+ precipitates are too narrow to be observed with 5x microscope objectives, 1+ precipitates are too narrow for 10x objectives. Thus, the rule uses the optical resolution windows of standard diagnostic microscope objectives to derive the width of the DAB-precipitates. The width is in turn correlated with color-intensity. Hereby, the more or less subjective estimation of IHC scores based only on the staining-intensity is replaced by a quasi-morphometric measurement. The principle seems universally applicable to immunohistochemical stainings of membrane-bound biomarkers that require an intensity-dependent scoring.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors
    Kaemmerer, Daniel
    Peter, Luisa
    Lupp, Amelie
    Schulz, Stefan
    Saenger, Joerg
    Baum, Richard Paul
    Prasad, Vikas
    Hommann, Merten
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2012, 5 (03): : 187 - 194
  • [32] HER2 and gastric cancer: a novel therapeutic target for trastuzumab
    Bouche, O.
    Penault-Llorca, F.
    BULLETIN DU CANCER, 2010, 97 (12) : 1429 - 1440
  • [33] HER2 testing in gastric cancer: An update
    Lucas Faria Abrahao-Machado
    Cristovam Scapulatempo-Neto
    World Journal of Gastroenterology, 2016, (19) : 4619 - 4625
  • [34] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676
  • [35] The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+in Breast Cancer
    Wu, Si
    Yue, Meng
    Zhang, Jun
    Li, Xiaoxian
    Li, Zaibo
    Zhang, Huina
    Wang, Xinran
    Han, Xiao
    Cai, Lijing
    Shang, Jiuyan
    Jia, Zhanli
    Wang, Xiaoxiao
    Li, Jinze
    Liu, Yueping
    MODERN PATHOLOGY, 2023, 36 (03)
  • [36] Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
    Lee, Hee Eun
    Park, Kyoung Un
    Yoo, Seol Bong
    Nam, Soo Kyung
    Park, Do Joong
    Kim, Hyung-Ho
    Lee, Hye Seung
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1448 - 1457
  • [37] Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer
    Furrer, Daniela
    Jacob, Simon
    Caron, Chantal
    Sanschagrin, Francois
    Provencher, Louise
    Diorio, Caroline
    ANTICANCER RESEARCH, 2016, 36 (09) : 4661 - 4666
  • [38] Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HEr2 status of the whole tumor
    Mueller-Holzner, E
    Fink, V
    Frede, T
    Marth, C
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (01) : 13 - 19
  • [39] Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor
    Elisabeth Mueller-Holzner
    Vroni Fink
    Thomas Frede
    Christian Marth
    Breast Cancer Research and Treatment, 2001, 69 : 13 - 19
  • [40] Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers
    Niu, Dongfeng
    Li, Lei
    Yu, Yang
    Zang, Wanchun
    Li, Zhongwu
    Zhou, Lixin
    Jia, Ling
    Rao, Guanhua
    Gao, Lianju
    Cheng, Gang
    Ji, Ke
    Lin, Dongmei
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2577 - 2585